IDEAYA's Eye Cancer Therapy Receives Breakthrough Therapy Designation From FDA

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

IDEAYA's Eye Cancer Therapy Receives Breakthrough Therapy Designation From FDA

, MT Newswires - 7:51 AM ET 3/31/2025 default

07:51 AM EDT, 03/31/2025 (MT Newswires) -- IDEAYA Biosciences ( IDYA ) said Monday the US Food and Drug Administration granted breakthrough therapy designation to its experimental neoadjuvant treatment, darovarsetib, to treat adult patients with primary uveal melanoma.

The company said the decision was supported by interim data from an ongoing phase 2 trial, which showed 82% ocular tumor shrinkage and 61% eye preservation rates in patients.

IDEAYA said it plans to initiate a phase 3 trial for the therapy in H1 2025.

The breakthrough therapy designation accelerates developing and reviewing promising therapies for serious conditions, offering benefits such as intensive FDA guidance and priority review.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.